Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
Li et al.
, Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron..
, Frontiers in Pediatrics, doi:10.3389/fped.2023.1160929
Retrospective 20 pediatric hematological disease patients in China, showing faster viral clearance with paxlovid, but slower resolution of fever.Confounding by contraindication. [Hoertel]
find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
resolution of fever, 51.3% higher, relative time 1.51, p = 0.008, treatment 9, control 11.
time to viral-, 57.6% lower, relative time 0.42, p = 0.03, treatment 9, control 11.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 25 Apr 2023, retrospective, China, peer-reviewed, 9 authors, study period 10 December, 2022 - 20 January, 2023.
email@example.com, firstname.lastname@example.org, email@example.com.
Medical University of Lublin, Poland
Azienda Ospedaliero Universitaria Consorziale
Policlinico di Bari, Italy
Medical University of Silesia, Poland
These authors have contributed equally to this
This article was submitted to Pediatric
Hematology and Hematological Malignancies, a
section of the journal Frontiers in Pediatrics
RECEIVED 07 February 2023
ACCEPTED 23 March 2023
PUBLISHED 25 April 2023
Li Y, Liu Y, Wen L, Chen H, Wang W, Tian M,
Cheng Y, Xue H and Chen C (2023) Clinical
efﬁcacy analysis of paxlovid in children with
hematological diseases infected with the
omicron SARS-CoV-2 new variant.
Front. Pediatr. 11:1160929.
© 2023 Li, Liu, Wen, Chen, Wang, Tian, Cheng,
Xue and Chen. This is an open-access article
distributed under the terms of the Creative
Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
TYPE Original Research
PUBLISHED 25 April 2023
Clinical efﬁcacy analysis of
paxlovid in children with
hematological diseases infected
with the omicron SARS-CoV-2
Yixian Li1†, Yong Liu1†, Luping Wen2, Hui Chen3, Wenqing Wang1,
Mengyao Tian1, Yucai Cheng1*, Hongman Xue1* and Chun Chen1*
Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The
Seventh Afﬁliated Hospital of Sun Yat-Sen University, Shenzhen, China, 2Department of Pharmacy, The
Seventh Afﬁliated Hospital of Sun Yat-Sen University, Shenzhen, China, 3Research Center, The Seventh
Afﬁliated Hospital of Sun Yat-sen University, Shenzhen, China
Objective: To summarize the clinical characteristics of children with
hematological malignancies co-infected with novel coronavirus and explore the
safety and effectiveness of Paxlovid treatment.
Methods: From December 10, 2022, to January 20, 2023, the clinical data of
children with hematological diseases diagnosed with novel coronavirus infection
in the outpatient and emergency department of the Seventh Afﬁliated Hospital
of Sun Yat-sen University were retrospectively analyzed.
Results: According to whether to give paxlovid or not, it is divided into group A
(paxlovid group) and group B (non-paxlovid group). The length of fever was 1–6
days in group A and 0–3 days in group B. The viral clearance time was shorter
in group A than in group B. The inﬂammatory indexes CRP and PCT were
signiﬁcantly higher in group A than in group B (P < 0.05). Twenty patients were
followed up for 1 month after leaving the hospital, and there were 5 cases of
reappearance of fever, 1 case of increased sleep, 1 case of physical fatigue and 1
case of loss of appetite within 2 weeks.
Conclusions: Paxlovid has no apparent adverse reactions in children 12 years old
and younger with underlying hematological diseases infected with the new
coronavirus. Focusing on the interaction between paxlovid and other drugs is
necessary during the treatment.
clinical efﬁcacy, PAXLOVID,..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.